ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Amazon Pharmacy adds automatic coupons to drop insulin prices

Amazon Pharmacy is automatically applying coupons to bring the cost of insulin down to as low as $35 a month so more patients can access the discounts promised by drug makers.

Amazon Pharmacy will release coupons that will automatically bring down the cost of insulin on more than a dozen insulin and diabetes care brands. 

The move will effectively help patients using the online pharmacy access discounts for the critical diabetes medicine that major drugmakers had promised to offer earlier this year. 

With the automatically applied discount, insulin from major drugmakers, including Novo Nordisk, Eli Lilly and Sanofi, will start at $35 a month, according to Amazon. 

ELI LILLY CAPS OUT-OF-POCKET COSTS FOR INSULIN EFFECTIVE IMMEDIATELY

According to the American Diabetes Association (ADA), over 37 million Americans are living with diabetes and 8.4 million Americans rely on insulin to survive. Insulin costs are typically 10 times higher in the U.S. than anywhere else in the world, the association said.

"Access to affordable diabetes medications and technology can help people living with diabetes stay healthy and avoid complications. Sadly, some of the more than 37 million Americans living with diabetes can’t afford the treatments they need to survive," said ADA CEO Charles Henderson said in a statement. 

Knowing that this is a burden faced by many, several drug companies pledged in March to slash the price of insulin, in some cases by as much as nearly 80%, by early 2024 in order to help more patients access the medication. 

HOUSE PASSES BILL CAPPING INSULIN AT $35 A MONTH FOR PATIENTS WITH INSURANCE

For instance, Danish drugmaker Novo Nordisk announced it is lowering the U.S. list prices of several insulin products by up to 75% for people living with type 1 and type 2 diabetes. 

At the same time, Sanofi announced that it will cut the list price of its most widely prescribed insulin in the U.S. by 78%. 

Eli Lilly also pledged to cut the price of its most commonly prescribed insulin by 70%. 

GET FOX BUSINESS ON THE GO BY CLICKING HERE

A provision in the Inflation Reduction Act was imposed in January that capped out-of-pocket costs for patients enrolled in Medicare at $35 per month. 

There is a higher prevalence of diabetes, nearly 30%, in Medicare patients, according to the U.S. Department of Health and Human Services (HHS). 

Medicare is the federal insurance program that's mainly for people who are at least 65 years old. People with permanent kidney failure or who receive disability benefits may also qualify.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.